Literature DB >> 30309777

Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives.

Robert Pirker1, Martin Filipits2.   

Abstract

Patients with early-stage non-small-cell lung cancer undergo surgery with curative intent. Many of these patients relapse and, therefore, adjuvant therapies are important for improving survival of these patients. Adjuvant chemotherapy has been established and increases the 5-year survival rate. Here, we discuss systemic treatment strategies for further improving outcome of patients with completely resected non-small-cell lung cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant chemotherapy; Immunotherapy; Prognosis; Surgery; Targeted therapy

Mesh：

Substances：

Year:  2018        PMID： 30309777     DOI： 10.1016/j.cllc.2018.09.016

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


  9 in total

1.  Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy.

Authors:  Ming Zhao; Jing Zhang; Siyu Chen; Yuqi Wang; Qing Tian
Journal:  Cancer Manag Res       Date:  2020-08-04       Impact factor: 3.989

Review 2.  Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives.

Authors:  Wenxin Luo; Zhoufeng Wang; Ting Zhang; Lan Yang; Jinghong Xian; Yalun Li; Weimin Li
Journal:  Precis Clin Med       Date:  2021-12-02

3.  Adjuvant chemotherapy as a risk factor for chronic postoperative pain after video-assisted thoracoscopic surgery: a 10-year single-centre retrospective study.

Authors:  Susie Yoon; Won-Pyo Hong; Hyundeok Joo; Dongyeon Jang; Samina Park; Ho-Jin Lee
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-01-22

4.  Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.

Authors:  Florian Eichhorn; Mark Kriegsmann; Laura V Klotz; Katharina Kriegsmann; Thomas Muley; Christiane Zgorzelski; Petros Christopoulos; Hauke Winter; Martin E Eichhorn
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

5.  Exploration of estrogen receptor-associated hub genes and potential molecular mechanisms in non-smoking females with lung adenocarcinoma using integrated bioinformatics analysis.

Authors:  Hao Wang; Zhihong Zhang; Ke Xu; Song Wei; Lailing Li; Lijun Wang
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

Review 6.  Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).

Authors:  Li-Chung Chiu; Shu-Min Lin; Yu-Lun Lo; Scott Chih-Hsi Kuo; Cheng-Ta Yang; Ping-Chih Hsu
Journal:  Vaccines (Basel)       Date:  2021-06-23

7.  Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.

Authors:  Xue Yan; Guowei Li
Journal:  Biosci Rep       Date:  2020-03-27       Impact factor: 3.840

8.  Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.

Authors:  Pei Zhang; Jianchun Duan; Hua Bai; Zhijie Wang; Shugeng Gao; Fengwei Tan; Yushun Gao; Xin Wang; Rui Wan; Jiachen Xu; Xiran He; Xiaoshuang Feng; Ruofei Yu; Jing Sun; Zhe Zhao; Kailun Fei; Ni Li; Jie He; Jie Wang
Journal:  Thorac Cancer       Date:  2020-10-27       Impact factor: 3.500

9.  Neoadjuvant chemotherapy combined with intraoperative radiotherapy is effective to prevent recurrence in high-risk non-small cell lung cancer (NSCLC) patients.

Authors:  Olga V Pankova; Evgeny O Rodionov; Sergey V Miller; Sergey A Tuzikov; Liubov A Tashireva; Tatiana S Gerashchenko; Evgeny V Denisov; Vladimir M Perelmuter
Journal:  Transl Lung Cancer Res       Date:  2020-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.